Briefly, a pre-clinical rat model was used and different tumor lines showed that 64Cu-ATSM was a valid PET hypoxia marker (correlation of the autoradiographic distributions with hypoxia markers as EF5, pimonidazole, and CAIX) for adenocarcinoma and glioma tumor cell line but a hypoxia-independent uptake of 64Cu-ATSM in fibrosarcoma was observed (22). This evidence concerns the gene CA9 and neoplasm.